Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Making the invisible visible: the availability and desirability of adherence data in routine CF care- findings from a national questionnaire survey.

Robinson L, Maguire C, Hoo ZH, Wildman MJ.

F1000Res. 2019 Nov 11;8:1904. doi: 10.12688/f1000research.21033.2. eCollection 2019.

2.

Investigating the Temporal Relationships between Symptoms and Nebuliser Adherence in People with Cystic Fibrosis: A Series of N-of-1 Observations.

Martin R, Arden M, Porritt J, Wildman M, Naughton F.

Healthcare (Basel). 2020 Jan 21;8(1). pii: E22. doi: 10.3390/healthcare8010022.

3.

Multicentre, randomised trial to investigate early nasal high-flow therapy in paediatric acute hypoxaemic respiratory failure: a protocol for a randomised controlled trial-a Paediatric Acute respiratory Intervention Study (PARIS 2).

Franklin D, Shellshear D, Babl FE, Schlapbach LJ, Oakley E, Borland ML, Hoeppner T, George S, Craig S, Neutze J, Williams A, Acworth J, McCay H, Wallace A, Mattes J, Gangathimn V, Wildman M, Fraser JF, Moloney S, Gavranich J, Waugh J, Hobbins S, Fahy R, Grew S, Gannon B, Gibbons K, Dalziel S, Schibler A; PARIS and PREDICT.

BMJ Open. 2019 Dec 18;9(12):e030516. doi: 10.1136/bmjopen-2019-030516.

4.

Regarding the article entitled "A smartphone application for reporting symptoms in adults with cystic fibrosis improves the detection of exacerbations: Results of a randomised controlled trial".

Hoo ZH, Wildman MJ.

J Cyst Fibros. 2019 Oct 31. pii: S1569-1993(19)30902-6. doi: 10.1016/j.jcf.2019.09.017. [Epub ahead of print] No abstract available.

PMID:
31678013
5.

Exploring the implications of different approaches to estimate centre-level adherence using objective adherence data in an adult cystic fibrosis centre - a retrospective observational study.

Hoo ZH, Curley R, Walters SJ, Campbell MJ, Wildman MJ.

J Cyst Fibros. 2020 Jan;19(1):162-167. doi: 10.1016/j.jcf.2019.10.008. Epub 2019 Oct 31.

PMID:
31678011
6.

Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Abbott L, Plummer A, Hoo ZH, Wildman M.

Cochrane Database Syst Rev. 2019 Sep 5;9:CD006682. doi: 10.1002/14651858.CD006682.pub6.

PMID:
31487382
7.

When Is Forgetting Not Forgetting? A Discursive Analysis of Differences in Forgetting Talk Between Adults With Cystic Fibrosis With Different Levels of Adherence to Nebulizer Treatments.

Drabble SJ, O'Cathain A, Arden MA, Hutchings M, Beever D, Wildman M.

Qual Health Res. 2019 Dec;29(14):2119-2131. doi: 10.1177/1049732319856580. Epub 2019 Jul 13.

PMID:
31303116
8.
9.

Intravenous antibiotic use and exacerbation events in an adult cystic fibrosis centre: A prospective observational study.

Hoo ZH, Bramley NR, Curley R, Edenborough FP, Walters SJ, Campbell MJ, Wildman MJ.

Respir Med. 2019 Jul - Aug;154:109-115. doi: 10.1016/j.rmed.2019.06.017. Epub 2019 Jun 18.

PMID:
31234038
10.

Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study.

Hind D, Drabble SJ, Arden MA, Mandefield L, Waterhouse S, Maguire C, Cantrill H, Robinson L, Beever D, Scott AJ, Keating S, Hutchings M, Bradley J, Nightingale J, Allenby MI, Dewar J, Whelan P, Ainsworth J, Walters SJ, O'Cathain A, Wildman MJ.

BMC Pulm Med. 2019 Apr 11;19(1):77. doi: 10.1186/s12890-019-0834-6.

11.

A pragmatic behavior-based habit index for adherence to nebulized treatments among adults with cystic fibrosis.

Hoo ZH, Wildman MJ, Campbell MJ, Walters SJ, Gardner B.

Patient Prefer Adherence. 2019 Feb 13;13:283-294. doi: 10.2147/PPA.S186417. eCollection 2019.

12.

Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework.

Arden MA, Drabble S, O'Cathain A, Hutchings M, Wildman M.

Br J Health Psychol. 2019 May;24(2):357-380. doi: 10.1111/bjhp.12357. Epub 2019 Mar 1.

13.

Identifying exceptional cystic fibrosis care services: combining statistical process control with focus groups.

MacNeill SJ, Pierotti L, Mohammed MA, Wildman M, Boote J, Harrison S, Carr SB, Cullinan P, Elston C, Bilton D.

Southampton (UK): NIHR Journals Library; 2019 Feb.

14.

Understanding FEV1 for the purpose of cystic fibrosis registry comparisons: Does bias in annual review FEV1 affect between-centre comparison within the UK? An analysis of registry data.

Hoo ZH, Campbell MJ, Walters SJ, Wildman MJ.

J Eval Clin Pract. 2020 Feb;26(1):229-235. doi: 10.1111/jep.13097. Epub 2019 Jan 25.

PMID:
30681238
15.

Submerged attached-growth reactors as lagoon retrofits for cold-weather ammonia removal: performance and sizing.

Mattson RR, Wildman M, Just C.

Water Sci Technol. 2018 Nov;78(8):1625-1632. doi: 10.2166/wst.2018.399.

PMID:
30500786
16.
17.

Patterns of regional lung physiology in cystic fibrosis using ventilation magnetic resonance imaging and multiple-breath washout.

Smith LJ, Collier GJ, Marshall H, Hughes PJC, Biancardi AM, Wildman M, Aldag I, West N, Horsley A, Wild JM.

Eur Respir J. 2018 Nov 8;52(5). pii: 1800821. doi: 10.1183/13993003.00821-2018. Print 2018 Nov.

PMID:
30361245
18.

Pragmatic criteria to define chronic pseudomonas aeruginosa infection among adults with cystic fibrosis.

Hoo ZH, Coates E, Maguire C, Cantrill H, Shafi N, Nash EF, McGowan A, Bourke SJ, Flight WG, Daniels TV, Nightingale JA, Allenby MI, Curley R, Wildman MJ.

Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2219-2222. doi: 10.1007/s10096-018-3358-8. Epub 2018 Aug 18. No abstract available.

PMID:
30121804
19.

The importance of data issues when comparing cystic fibrosis registry outcomes between countries: Are annual review FEV1 in the UK only collected when subjects are well?

Hoo ZH, Curley R, Campbell MJ, Walters SJ, Wildman MJ.

J Eval Clin Pract. 2018 Aug;24(4):745-751. doi: 10.1111/jep.12967. Epub 2018 Jun 14.

20.

Role of habit in treatment adherence among adults with cystic fibrosis.

Hoo ZH, Gardner B, Arden MA, Waterhouse S, Walters SJ, Campbell MJ, Hind D, Maguire C, Dewar J, Wildman MJ.

Thorax. 2019 Feb;74(2):197-199. doi: 10.1136/thoraxjnl-2017-211453. Epub 2018 Jun 9.

PMID:
29886416
21.

Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic Pseudomonas infection.

Mann N, Murray S, Hoo ZH, Curley R, Wildman MJ.

Version 2. F1000Res. 2017 Dec 1 [revised 2018 Jan 1];6:2079. doi: 10.12688/f1000research.13298.2. eCollection 2017.

22.

Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision.

Hoo ZH, Edenborough FP, Curley R, Prtak L, Dewar J, Allenby MI, Nightingale JA, Wildman MJ.

Eur J Clin Microbiol Infect Dis. 2018 Apr;37(4):735-743. doi: 10.1007/s10096-017-3168-4. Epub 2018 Jan 6.

23.

Do cystic fibrosis centres with the lowest FEV1 still use the least amount of intravenous antibiotics? A registry-based comparison of intravenous antibiotic use among adult CF centres in the UK.

Hoo ZH, Campbell MJ, Curley R, Walters SJ, Wildman MJ.

J Cyst Fibros. 2018 May;17(3):360-367. doi: 10.1016/j.jcf.2017.10.005. Epub 2017 Oct 23.

24.

Rescue therapy within the UK Cystic Fibrosis Registry: An exploration of predictors of intravenous antibiotic use amongst adults with CF.

Hoo ZH, Wildman MJ, Curley R, Walters SJ, Campbell MJ.

Respirology. 2018 Feb;23(2):190-197. doi: 10.1111/resp.13174. Epub 2017 Sep 14.

25.

An empirical method to cluster objective nebulizer adherence data among adults with cystic fibrosis.

Hoo ZH, Campbell MJ, Curley R, Wildman MJ.

Patient Prefer Adherence. 2017 Mar 24;11:631-642. doi: 10.2147/PPA.S131497. eCollection 2017.

26.

Potential effect of centre size on continuity of care and healthcare performance.

Hoo ZH, Curley RE, Wildman MJ.

BMJ. 2017 Mar 27;356:j1514. doi: 10.1136/bmj.j1514. No abstract available.

27.

An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis.

Tappenden P, Sadler S, Wildman M.

Pharmacoeconomics. 2017 Jun;35(6):647-659. doi: 10.1007/s40273-017-0500-x.

28.

Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Plummer A, Wildman M, Gleeson T.

Cochrane Database Syst Rev. 2016 Sep 1;9:CD006682. doi: 10.1002/14651858.CD006682.pub5. Review. Update in: Cochrane Database Syst Rev. 2019 Sep 05;9:CD006682.

29.

Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate "normative adherence".

Hoo ZH, Curley R, Campbell MJ, Walters SJ, Hind D, Wildman MJ.

Patient Prefer Adherence. 2016 May 23;10:887-900. doi: 10.2147/PPA.S105530. eCollection 2016.

30.

Promoting adherence to nebulized therapy in cystic fibrosis: poster development and a qualitative exploration of adherence.

Jones S, Babiker N, Gardner E, Royle J, Curley R, Hoo ZH, Wildman MJ.

Patient Prefer Adherence. 2015 Aug 3;9:1109-20. doi: 10.2147/PPA.S82896. eCollection 2015.

31.

Airway clearance techniques used by people with cystic fibrosis in the UK.

Hoo ZH, Daniels T, Wildman MJ, Teare MD, Bradley JM.

Physiotherapy. 2015 Dec;101(4):340-8. doi: 10.1016/j.physio.2015.01.008. Epub 2015 Mar 14.

32.

Regarding the article entitled "Iron supplementation does not worsen respiratory health or alter the sputum microbiome in cystic fibrosis".

Hoo ZH, Wildman MJ.

J Cyst Fibros. 2015 Jan;14(1):158-9. doi: 10.1016/j.jcf.2014.06.002. Epub 2014 Jun 25. No abstract available.

33.

Moving cystic fibrosis care from rescue to prevention by embedding adherence measurement in routine care.

Wildman MJ, Hoo ZH.

Paediatr Respir Rev. 2014 Jun;15 Suppl 1:16-8. doi: 10.1016/j.prrv.2014.04.007. Epub 2014 Apr 13. Review.

PMID:
24835307
34.

Exploration of the impact of 'mild phenotypes' on median age at death in the U.K. CF registry.

Hoo ZH, Wildman MJ, Teare MD.

Respir Med. 2014 May;108(5):716-21. doi: 10.1016/j.rmed.2014.02.012. Epub 2014 Mar 12.

35.

Successful use of haemodialysis to treat phenobarbital overdose.

Hoyland K, Hoy M, Austin R, Wildman M.

BMJ Case Rep. 2013 Nov 21;2013. pii: bcr2013010011. doi: 10.1136/bcr-2013-010011.

36.

Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Plummer A, Wildman M.

Cochrane Database Syst Rev. 2013 May 31;(5):CD006682. doi: 10.1002/14651858.CD006682.pub4. Review.

PMID:
23728662
37.

Intravenous iron among cystic fibrosis patients.

Hoo ZH, Wildman MJ.

J Cyst Fibros. 2012 Dec;11(6):560-2. doi: 10.1016/j.jcf.2012.05.002. Epub 2012 Jun 19. No abstract available.

38.

Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Plummer A, Wildman M.

Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006682. doi: 10.1002/14651858.CD006682.pub3. Review. Update in: Cochrane Database Syst Rev. 2013;5:CD006682.

PMID:
21249681
39.

Predicting mortality for patients with exacerbations of COPD and Asthma in the COPD and Asthma Outcome Study (CAOS).

Wildman MJ, Sanderson C, Groves J, Reeves BC, Ayres J, Harrison D, Young D, Rowan K.

QJM. 2009 Jun;102(6):389-99. doi: 10.1093/qjmed/hcp036. Epub 2009 Apr 15.

PMID:
19369483
40.

Survival and quality of life for patients with COPD or asthma admitted to intensive care in a UK multicentre cohort: the COPD and Asthma Outcome Study (CAOS).

Wildman MJ, Sanderson CF, Groves J, Reeves BC, Ayres JG, Harrison D, Young D, Rowan K.

Thorax. 2009 Feb;64(2):128-32. doi: 10.1136/thx.2007.091249. Epub 2008 Oct 13.

PMID:
18852157
41.

Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Fernandes B, Plummer A, Wildman M.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006682. doi: 10.1002/14651858.CD006682.pub2. Review. Update in: Cochrane Database Syst Rev. 2011;(1):CD006682.

PMID:
18425963
43.
44.

Experimental evidence from H/D exchange studies for the failure of direct C-C coupling mechanisms in the methanol-to-olefin process catalyzed by HSAPO-34.

Marcus DM, McLachlan KA, Wildman MA, Ehresmann JO, Kletnieks PW, Haw JF.

Angew Chem Int Ed Engl. 2006 May 5;45(19):3133-6. No abstract available.

PMID:
16570333
45.

Socioeconomic status and outcome from intensive care in England and Wales.

Hutchings A, Raine R, Brady A, Wildman M, Rowan K.

Med Care. 2004 Oct;42(10):943-51.

PMID:
15377926
46.

Sources of variability in uncertain medical decisions in the ICU: a process tracing study.

Kostopoulou O, Wildman M.

Qual Saf Health Care. 2004 Aug;13(4):272-80.

47.

Variations in mortality in acute COPD may reflect nihilism as well as resources.

Wildman MJ.

Thorax. 2004 Jun;59(6):538; author reply 538. No abstract available.

48.

Variation in intubation decisions for patients with chronic obstructive pulmonary disease in one critical care network.

Wildman MJ, O'Dea J, Kostopoulou O, Tindall M, Walia S, Khan Z.

QJM. 2003 Aug;96(8):583-91.

PMID:
12897344
49.

Q fever: still a mysterious disease.

Wildman MJ, Ayres JG.

QJM. 2002 Dec;95(12):833-4. No abstract available.

PMID:
12524714
50.

GABA-like immunoreactivity in nonspiking interneurons of the locust metathoracic ganglion.

Wildman M, Ott SR, Burrows M.

J Exp Biol. 2002 Dec;205(Pt 23):3651-9.

Supplemental Content

Loading ...
Support Center